WaveMan · Form 4
Siegall Clay B insider trades
> Search tickers & screens ⌘K
LIVE

Siegall Clay B insider trades

Siegall Clay B has filed 38 Form 4s with the SEC that we hold, for SGEN (President & CEO, Director), Immunome Inc. (IMNM) (President and CEO, Director), Shattuck Labs, Inc. (STTK) (Director) and TRML (Director), among 5 companies in all. Across all of them we count 12 purchases worth $7.5M and 52 sales worth $41.5M reported on Form 4. In the last 12 months: 5 purchases ($2.0M) and 0 sales ($0). The largest single trade was a sale of 32,800 shares of SGEN worth $5.5M, dated 2021-08-30. The first filing on our record is dated 2021-07-06 and the latest 2026-07-27.

SGEN

President & CEO, Director · 14 filings · 52 purchases and sales
Trade dateCodeSharesValue as filedFiled
2021-07-01S, sale reported on Form 43,432$544.5K2021-07-06
2021-07-01S, sale reported on Form 44,488$704.3K2021-07-06
2021-07-01S, sale reported on Form 46,165$973.6K2021-07-06
2021-07-02S, sale reported on Form 45,191$808.2K2021-07-06
2021-07-02S, sale reported on Form 47,412$1.2M2021-07-06
2021-07-02S, sale reported on Form 42,355$370.5K2021-07-06
2021-07-02S, sale reported on Form 4310$49.1K2021-07-06
2021-08-05S, sale reported on Form 44,813$788.4K2021-08-06
2021-08-05S, sale reported on Form 42,300$379.0K2021-08-06
2021-08-05S, sale reported on Form 49,262$1.5M2021-08-06
2021-08-05S, sale reported on Form 47,185$1.2M2021-08-06
2021-08-06S, sale reported on Form 42,117$339.7K2021-08-06
2021-08-06S, sale reported on Form 43,676$585.4K2021-08-06
2021-08-16S, sale reported on Form 42,789$431.0K2021-08-18
2021-08-27S, sale reported on Form 412,213$2.1M2021-08-31
2021-08-27S, sale reported on Form 42,081$354.1K2021-08-31
2021-08-30S, sale reported on Form 42,906$487.1K2021-08-31
2021-08-30S, sale reported on Form 432,800$5.5M2021-08-31
2021-08-31S, sale reported on Form 44,787$801.9K2021-09-02
2021-08-31S, sale reported on Form 49,564$1.6M2021-09-02
2021-08-31S, sale reported on Form 48,662$1.5M2021-08-31
2021-08-31S, sale reported on Form 41,770$297.7K2021-08-31
2021-12-07S, sale reported on Form 414,691$2.2M2021-12-09
2021-12-07S, sale reported on Form 411,522$1.7M2021-12-09
2021-12-07S, sale reported on Form 45,348$804.2K2021-12-09
2021-12-07S, sale reported on Form 41,650$241.8K2021-12-09
2021-12-07S, sale reported on Form 412,238$1.8M2021-12-09
2021-12-20S, sale reported on Form 41,227$183.9K2021-12-22
2022-01-07S, sale reported on Form 41,100$161.9K2022-01-11
2022-01-07S, sale reported on Form 43,221$469.8K2022-01-11
2022-01-07S, sale reported on Form 44,560$660.4K2022-01-11
2022-01-07S, sale reported on Form 48,163$1.2M2022-01-11
2022-02-07S, sale reported on Form 43,574$496.7K2022-02-09
2022-02-07S, sale reported on Form 44,084$575.1K2022-02-09
2022-02-07S, sale reported on Form 4100$13.7K2022-02-09
2022-02-07S, sale reported on Form 4300$42.5K2022-02-09
2022-02-07S, sale reported on Form 48,985$1.3M2022-02-09
2022-03-07S, sale reported on Form 4100$13.6K2022-03-09
2022-03-07S, sale reported on Form 43,900$517.6K2022-03-09
2022-03-07S, sale reported on Form 44,000$542.5K2022-03-09
2022-03-07S, sale reported on Form 42,400$320.9K2022-03-09
2022-03-07S, sale reported on Form 46,643$895.1K2022-03-09
2022-04-07S, sale reported on Form 42,100$320.4K2022-04-08
2022-04-07S, sale reported on Form 44,692$719.7K2022-04-08
2022-04-07S, sale reported on Form 42,400$370.5K2022-04-08
2022-04-07S, sale reported on Form 43,828$596.5K2022-04-08
2022-04-07S, sale reported on Form 41,649$249.7K2022-04-08
2022-04-07S, sale reported on Form 41,900$297.3K2022-04-08
2022-04-07S, sale reported on Form 4474$74.5K2022-04-08
2022-04-20S, sale reported on Form 41,885$272.0K2022-04-22
2022-05-12S, sale reported on Form 410,593$1.3M2022-05-13
2022-05-12S, sale reported on Form 46,450$813.9K2022-05-13

Immunome Inc. (IMNM)

President and CEO, Director · 12 filings · 11 purchases and sales
Trade dateCodeSharesValue as filedFiled
2023-10-02P, purchase reported on Form 4169,204$1,000.0K2023-10-04
2024-05-20P, purchase reported on Form 479,566$1.1M2024-05-21
2024-05-21P, purchase reported on Form 420,434$281.6K2024-05-21
2024-11-21P, purchase reported on Form 466,057$630.2K2024-11-25
2024-11-22P, purchase reported on Form 433,943$332.0K2024-11-25
2025-01-31P, purchase reported on Form 4150,000$1.2M2025-02-03
2025-03-26P, purchase reported on Form 4137,100$999.5K2025-03-26
2025-12-18P, purchase reported on Form 446,511$1,000.0K2025-12-18
2025-12-19P, purchase reported on Form 47,278$149.1K2025-12-22
2025-12-30P, purchase reported on Form 44,729$100.0K2025-12-30
2026-03-27P, purchase reported on Form 425,450$500.6K2026-03-31

Shattuck Labs, Inc. (STTK)

Director · 7 filings · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2026-06-09P, purchase reported on Form 462,500$250.0K2026-06-11

TRML

Director · 4 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Nurix Therapeutics, Inc. (NRIX)

Director · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1167496) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms